GLMD — Galmed Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $5.75m
- -$13.30m
- 23
- 55
- 49
- 37
Annual cashflow statement for Galmed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.8 | -32.5 | -17.9 | -6.91 | -7.52 |
| Depreciation | |||||
| Non-Cash Items | 1.34 | 1.98 | 1.78 | 0.612 | 2.28 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.1 | -2.45 | -2.45 | 0.132 | -0.728 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26.3 | -32.9 | -18.5 | -6.14 | -5.88 |
| Capital Expenditures | -0.044 | -0.011 | -0.004 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 16.6 | 11.5 | 17.6 | 0.8 | -1.11 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 16.5 | 11.5 | 17.6 | 0.8 | -1.11 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.768 | 17.4 | 0.07 | 6.18 | 8.79 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -8.98 | -4.06 | -0.868 | 0.848 | 1.79 |